Home > Boards > US Listed > Biotechs >

Cel-Sci (CVM)

CVM RSS Feed
Add CVM Price Alert      Hide Sticky   Hide Intro
Moderator: Golden_Cross, Foxwoods Man, drkazmd65, pijoe, Charmed7713, Dudmuffin
Search This Board: 
Last Post: 10/21/2019 11:03:53 PM - Followers: 270 - Board type: Free - Posts Today: 0

 Cel-Sci Corporation (CVM)

http://www.cel-sci.com/

https://www.youtube.com/watch?v=auAihG3rtC4

Products In Development

Multikine® (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this page as Multikine*.

CANCER - MULTIKINE

Multikine, CEL-SCI's lead investigational immunotherapy, is an immunotherapeutic agent that is being developed as a potential first-line treatment for advanced primary head and neck cancer. If it were to be approved for use following completion of CEL-SCI's clinical development program, Multikine would be a different kind of therapy in the fight against cancer; one that appears to have the potential to work with the body's natural immune system in the fight against tumors.

Multikine may also have the potential to be a first in a new class of cancer immunotherapy drugs. It is the first investigational combination immunotherapy thought to have both passive and active immune properties.  More...

INFECTIOUS DISEASES - L.E.A.P.S.(TM)**

L.E.A.P.S is a patented, T-cell modulation, peptide epitope delivery technology that enables CEL-SCI to design and synthesize proprietary peptide immunogens. L.E.A.P.S. compounds consist of a small T-cell binding peptide ligand linked with a disease-associated peptide antigen.

This new technology has been shown the potential in several animal models to preferentially direct immune response to a cellular (e.g., T-cell), humoral (antibody) or mixed pathway. Diseases for which antigenic epitope sequences have been identified, such as some infectious diseases, cancer, autoimmune diseases, allergic asthma and allergy, and select CNS diseases (e.g., Alzheimer's) may be potential candidates for development using this technology platform.  More...

 

* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or by any other regulatory agency. Similarly, its safety of efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data summarized on this page or elsewhere on this website involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.

** L.E.A.P.S. is the trademark of CEL-SCI for this investigational platform technology, and this proprietary name is subject to FDA review. No L.E.A.P.S. product has been approved for sale, barter or exchange by the FDA or any other regulatory agency for any use to treat disease in animals or humans. The safety or efficacy of these products has not been established for any use. Lastly, no definitive conclusions can be drawn from these early-phase, preclinical-trials data involving these investigational products

Partnering Philosophy & Corporate Partners

CEL-SCI's partnering philosophy is guided by the belief that any partnership entered into should serve the best interests of: 

  1. The patients who are/will be treated,
    The scientific, clinical, and commercial development of the medicine and
    CEL-SCI's shareholders.

CEL-SCI is open to any reasonable partnership proposals that will accelerate its being able to bring its medicines to market.

Multikine® (Leukocyte Interleukin, Injection):

Multikine (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this page as Multikine*.

CEL-SCI has a unique expertise in the development and manufacture of complex biologics. CEL-SCI is not a company that markets and sells drug products at the current time. Regardless, CEL-SCI believes it will be capable of marketing and selling Multikine on its own for head and neck cancer in both the United States and Europe if and once it is approved by the FDA (or EU regulators). Since its primary target is head & neck cancer surgeons, a rather small audience, CEL-SCI does not believe that a large sales force will be needed to commercialize Multikine, if and once it is approved by the FDA (or EU regulators) following the review of the total Multikine Biologics License Application.

Current Corporate Partners:

  1. Byron Biopharma
     
      a. Agreement Signed March 2009  
      b. Territory - Republic of South Africa  
      c. Revenue Share  

    Teva Pharmaceuticals Industries Ltd.
     
      a. Agreement Signed August 2008  
      b. Territory - Israel, Turkey, expanded to also cover Serbia and Croatia in August 2011.  
      c. Revenue Share  
      d. Website - http://www.tevapharm.com/  

     
    Orient Europharma Co. Ltd.
     
      a. Agreement Signed November 2000  
      b. Territory - Taiwan, Singapore, Hong Kong, Malaysia, expanded to also cover South Korea, the Philippines, Australia and New Zealand in the Fall of 2008.  
      c. Revenue Share  
      d. Website - http://www.oep.com.tw/  

     
    IDC-GP Pharm LLC 
     
      a. Agreement signed August 2011  
      b. Territory - Argentina and Venezuela  
      c. Revenue Share  
      d. Website - http://www.gp-pharm.com/  

     

Other Partnering Possibilities:

Based on the Company's L.E.A.P.S.TM** technology, as long as a disease epitope is available, CEL-SCI may be able to develop an effective treatment/vaccine using the L.E.A.P.S. technology.  The two leading candidates derived from this technology are the H1N1 treatment being developed as a possible treatment option for hospitalized patients and the Rheumatoid Arthritis treatment vaccine currently being tested in animal models of the disease.

 

* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data summarized on this page or elsewhere on this website involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.

** L.E.A.P.S. is the trademark of CEL-SCI for this investigational platform technology, and this proprietary name is subject to FDA review. No L.E.A.P.S. product has been approved for sale, barter or exchange by the FDA or any other regulatory agency for any use to treat disease in animals or humans. The safety or efficacy of these products has not been established for any use. Lastly, no definitive conclusions can be drawn from these early-phase, preclinical-trials data involving these investigational products.

https://www.prnewswire.com/news-releases/biotech-brief-growing-number-of-ongoing-clinical-trials-for-leukemia-aml-brings-new-hope-300827745.html

http://KillCVMShorts.com/faqs

http://KillCVMShorts.com/idmc

http://KillCVMShorts.com

http://stockcharts.com/freecharts/gallery.html?CVM

http://finance.yahoo.com/q?s=cvm&ql=1

http://stockcharts.com/h-sc/ui?s=CVM&p=D&yr=3&mn=0&dy=0&id=p60195179833

https://seekingalpha.com/instablog/50299941-cvm4life/5309598-setting-record-straight-cel-sci

https://seekingalpha.com/article/4275913-cel-sci-verge-approval#alt2

CVM shares held by iHub investors :

https://docs.google.com/spreadsheets/d/1aU3buYiKiQZDyNPRIBZWGoUk37TrlSjJ/edit#gid=1952396312

https://seekingalpha.com/article/4275913-cel-sci-verge-approval#alt2














 

CVM
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
CVM News: Current Report Filing (8-k) 10/15/2019 09:55:26 AM
CVM News: CEL-SCI Reports Recent Data Review by the Independent Data Monitoring Committee for Its Pivotal Phase 3 Head & Neck Cancer St... 10/15/2019 08:30:00 AM
CVM News: Current Report Filing (8-k) 10/15/2019 06:56:09 AM
CVM News: Statement of Changes in Beneficial Ownership (4) 10/01/2019 04:44:59 PM
CVM News: Statement of Changes in Beneficial Ownership (4) 10/01/2019 04:41:49 PM
PostSubject
#19754  Sticky Note Welcome CVM Newbies sushifishman 04/06/19 08:25:19 AM
#26530   Non related "events" will only make the greens12 10/21/19 11:03:53 PM
#26529   To quote Aaron Rodgers R-E-L-A-X Biobonic 10/21/19 10:14:05 PM
#26528   Congrats!... Keep accumulating and someday it's going pijoe 10/21/19 04:14:27 PM
#26527   Yup...and some more mid-day purchased April 10's found Foxwoods Man 10/21/19 04:06:09 PM
#26526   We will have a nice, full recovery.. I pijoe 10/21/19 04:00:35 PM
#26525   It is an opinion. Every trader and investor conix 10/21/19 02:20:00 PM
#26524   Thanks whom ever...Picked up 3k more shares...GO CVM$$$$ PARker1703 10/21/19 01:52:56 PM
#26523   Is that a reason? An excuse??? An opinion? yankeesnyc27 10/21/19 01:47:18 PM
#26522   This price swoon should not have been unexpected. conix 10/21/19 01:27:11 PM
#26521   Look at Yahoo M/B AND S/A..... talked about yankeesnyc27 10/21/19 01:17:25 PM
#26520   Not familiar with the MRK post. Where is/was Trustbaby 10/21/19 01:06:40 PM
#26519   Hey TRUST..... "Trust everyone, but cut the cards" yankeesnyc27 10/21/19 12:58:37 PM
#26518   Yank!!!!! Trustbaby 10/21/19 12:38:29 PM
#26517   RE: MRK, seekina alpha ****DISCLAIMER***** "PLEASE NOTE; yankeesnyc27 10/21/19 12:35:45 PM
#26516   "Its just a game that we used to play RobotDroid 10/21/19 12:08:43 PM
#26515   Hope no bad news coming out steve2150 10/21/19 11:43:13 AM
#26514   We all do. When the going gets weird, RobotDroid 10/21/19 11:38:39 AM
#26513   I hate this!! fluteman 10/21/19 11:31:51 AM
#26512   Well, with zero news pending as far as RobotDroid 10/21/19 11:15:45 AM
#26511   Droid, conspiracy theories about shorts. fluteman 10/21/19 11:11:30 AM
#26510   Nothing to report, and if you mean the RobotDroid 10/21/19 10:53:52 AM
#26509   Isn't this silence just giving the shorts exactly thinkingonlygreen 10/21/19 10:45:48 AM
#26508   Hey dyp - s Chuckster1 10/21/19 10:31:24 AM
#26507   Today or Tomorrow? sab63090 10/21/19 10:10:00 AM
#26506   looking better dyp 10/21/19 09:53:33 AM
#26505   @lightrock I guess my point is that we have sab63090 10/21/19 09:29:41 AM
#26504   I made about $500 on it the other day lightrock 10/21/19 08:21:52 AM
#26503   Where do we stand with $TEVA? sab63090 10/21/19 08:03:49 AM
#26502   ICONplc.com I just noticed their ad: sab63090 10/21/19 07:58:59 AM
#26501   Fosco thinks the dropouts have to be either lightrock 10/21/19 07:19:20 AM
#26500   If we believe the leak from Ergomed that lightrock 10/21/19 07:11:18 AM
#26499   Hi guys, the one thing that keeps bothering FINLI 10/21/19 02:57:33 AM
#26498   Chart conix 10/20/19 11:31:35 PM
#26497   @george Not sure about that, since the data has sab63090 10/20/19 11:45:43 AM
#26496   @sab funny you say that about fear and georgebailey 10/20/19 10:00:16 AM
#26495   Option premiums and data read out: sab63090 10/20/19 07:52:07 AM
#26494   Remitte thx got it georgebailey 10/19/19 09:17:27 PM
#26493   Yes we were, a worthy cause. RobotDroid 10/19/19 10:49:03 AM
#26492   Georgebailey - DRCS is the guy from Europe remittekram 10/19/19 08:55:57 AM
#26491   Here’s the PR The_Q 10/19/19 06:49:32 AM
#26490   Lightrock, fascinating & thanks. It sounds you think Trustbaby 10/19/19 12:01:22 AM
#26489   @Trust I don't know, but my back of the lightrock 10/18/19 11:18:03 PM
#26488   Lightrock, what would that timeline look like? Trustbaby 10/18/19 09:12:14 PM
#26487   Who is DRCS ? georgebailey 10/18/19 09:09:31 PM
#26486   @sushi It was MY point to say that it lightrock 10/18/19 08:24:25 PM
#26485   Thanks Light I really appreciate you and greens12 10/18/19 05:04:13 PM
#26484   @Light sushifishman 10/18/19 04:21:56 PM
#26483   You gotta figure somebody will want to look lightrock 10/18/19 04:04:16 PM
#26482   @staticmirror79 Sorry, just got back from outside on this sab63090 10/18/19 03:50:47 PM
#26481   Sab, staticmirror79 10/18/19 01:57:27 PM
PostSubject